Trifluridine & Tipiracil
- TRADE NAMES: Lonsurf (Monarch); TAS-102
- INDICATIONS: Metastatic colorectal cancer in patients who have been previously treated with fluoropyrimidine-, oxaliplatin-and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Thymidine phosphorylase inhibitor, Thymidine-based nucleoside analogue
- HALF-LIFE: 2 hours
FDA APPROVAL DATE: 09/22/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
Can cause fetal harm
See also separate entry for trifluridine.
Please login to see the rest of this drug profile
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of Trifluridine & Tipiracil in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/18/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric